ZLN-024

Research use only, not for human use.

A novel AMPK allosteric activator that has no effect on mitochondrial function or the ADP/ATP ratio; directly activate recombinant AMPK α1β1γ1 and its homologue α2β1γ1 with EC50 of 0.42 uM and 0.95 uM, respectively.

A novel AMPK allosteric activator that has no effect on mitochondrial function or the ADP/ATP ratio; directly activate recombinant AMPK α1β1γ1 and its homologue α2β1γ1 with EC50 of 0.42 uM and 0.95 uM, respectively; also directly activate recombinant AMPK α1β2γ1 (EC50=1.1 μuM) and AMPK α2β2γ1 (EC50=0.13 uM); activates AMPK in L6 myotubes and stimulates glucose uptake and fatty acid oxidation; improves glucose tolerance, liver tissue weight, triacylglycerol and decreases the total cholesterol content in db/db mice (15 mg/kg/day).Diabetes Preclinical

ZLN024

Membrane Transporter/Ion Channel

AMPK

AMPK

Metabolic Disease

Diabetes

723249-01-2

325.22

C13H13BrN2OS

>98% (HPLC)

10 mM in DMSO

CC1=CC(=C(C=C1)OCCSC2=NC=CC=N2)Br

Pyrimidine, 2-[[2-(2-bromo-4-methylphenoxy)ethyl]thio]-

(-20℃)

With Ice Pack

≥ 2 years